Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sipcam pacific australia pty. limited - bacillus thuringiensis subspecies kurstaki strain sa-11 - water dispersible granule - bacillus thuringiensis subspecies kurstaki strain sa-11 biological-organism-bt-kurstak active 0.0 p - insecticide - amenity tree | cereal grain | forestry | fruit | general agricultural use | herb | non-agricultural area - general | oilseed cro - armyworm | cabbage moth | cabbage white butterfly | helicoverpa armigera | light brown apple moth | looper | native budworm or bollworm | painted vine moth | pear looper | soybean looper | vine moth | bollworm | corn earworm | cotton bollworm | diachrysia orichalcea | diamondback moth | heliothis | looper caterpillars | native bollworm | spodoptera spp. | tobacco budworm | tomato grub | twig looper

Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

rufus & coco pty. ltd. - bifidobacterium bifidum; enterococcus faecium; lactobacillus delbrueckii subspecies bulgaricus; lactobacillus acidophilus; lactobacillus plantarum; lactobacillus rhamnosus; streptococcus salivarius subspecies thermophilus - oral powder, pre-mix - bifidobacterium bifidum biological-organism active 180.0 m cfu/g; enterococcus faecium biological-organism active 180.0 m cfu/g; lactobacillus delbrueckii subspecies bulgaricus biological-organism active 180.0 m cfu/g; lactobacillus acidophilus biological-organism active 180.0 m cfu/g; lactobacillus plantarum biological-organism active 180.0 m cfu/g; lactobacillus rhamnosus biological-organism active 180.0 m cfu/g; streptococcus salivarius subspecies thermophilus biological-organism active 180.0 m cfu/g - nutrition & metabolism - animal | birds | dog - puppy | kitten | aviary bird | breeders | broilers | budgerigars | canaries | chickens | chooks | domesti - diarrhoea | intestinal dysfunction | re-establishment of gut microflora | stress | absorptive | acute diarrhoea | acute intestinal catarrh | avian blackhead | bacterial enteritis | blackhead | chronic diarrhoea | coccidiosis | dietary factors | dietary upset | enteritis | feed conversion | flatulance | fluid loss | following antibiotic use | gastro-intestinal | gram negative bacteria | growth rate | k88+ serotypes of e.coli | nesting diarrhoea | non-specific irritants | poisoning | post-antibiotic therapy | postweaning scours | prophylactic | scours | streptomycin sensitive bacteri | sulphadiazine sensitive bacter | sulphonamide sensitive bacteri | trichomoniasis | trimethoprim sensitive bacteri | white scours

Israel - engelsk - Ministry of Health

novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.1 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Israel - engelsk - Ministry of Health

novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.05 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Israel - engelsk - Ministry of Health

novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.5 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: carcinoid tumours with features of the carcinoid syndrome. vipomas . glucagonomas . gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Den Europæiske Union - engelsk - EMA (European Medicines Agency)

tigenix n.v. - characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins - cartilage diseases - other drugs for disorders of the musculo-skeletal system - repair of single symptomatic cartilage defects of the femoral condyle of the knee (international cartilage repair society [icrs] grade iii or iv) in adults.concomitant asymptomatic cartilage lesions (icrs grade i or ii) might be present. demonstration of efficacy is based on a randomised controlled trial evaluating the efficacy of chondrocelect in patients with lesions between 1 and 5 cm².

Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

specialist sales pty ltd - fluazuron; 1-octyl-2-pyrrolidinone; 1-dodecyl-2-pyrrolidinone; 1-methyl-2-pyrrolidinone - topical solution/suspension - fluazuron ungrouped active 25.0 g/l; 1-octyl-2-pyrrolidinone ungrouped other 100.0 g/l; 1-dodecyl-2-pyrrolidinone ungrouped other 0.0 g/l; 1-methyl-2-pyrrolidinone solvent other 415.0 g/l - parasiticides

Irland - engelsk - HPRA (Health Products Regulatory Authority)

pharmaq as - aeromonas salmonicida subspecies salmonicida; al 2017; listonella anguillarum serotype o1; al 112; listonella anguillarum serotype o2a; al 104 - emulsion for injection - . - aeromonas + vibrio - atlantic salmon - immunological - inactivated vaccine

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

abacus dx pty ltd - ct974 - clinical chemistry-specific protein ivds - ivds intended to be used as quality control material to monitor laboratory measurement procedures of clinical chemistry specific proteins.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

abacus dx pty ltd - ct974 - clinical chemistry-specific protein ivds - ivds that are intended to be used for the qualitative and/or quantitative determination of proteins specific to clinical chemistry, in a clinical specimen.